Application of traditional Chinese medicine composition in preparation of medicine for treating hysteromyoma

Abstract

The invention belongs to the technical field of medicines, and particularly relates to application of a traditional Chinese medicine composition in preparation of a medicine for treating hysteromyoma. The traditional Chinese medicine composition is prepared from the following raw materials: 1-25 parts of peach kernel, 2-40 parts of myrrh, 2-40 parts of radix salviae miltiorrhizae, 2-20 parts of radix paeoniae rubra, 2-20 parts of safflower, 2-30 parts of herba lycopi, 2-20 parts of cowherb seed, 2-30 parts of spina gleditsiae, 2-60 parts of herba patriniae, 2-60 parts of dandelion, 1-25 parts of szechwan chinaberry fruit, 2-40 parts of radix angelicae, 2-40 parts of pyrrosia lingua and 1-20 parts of fructus lycii. The traditional Chinese medicine composition has a remarkable curative effect on hysteromyoma, has no toxic or side effect, and provides an important clinical value for overcoming the defects of few Chinese patent medicine varieties and poor curative effect in the current market.

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and particularly relates to application of a traditional Chinese medicine composition in preparing a medicine for treating uterine fibroids. Background Art

[0002] Uterine fibroids are the most common benign tumors in the female reproductive organs and one of the most common tumors in the human body. Based on their relationship with the uterine wall, uterine fibroids can be divided into uterine body fibroids (about 90%) and cervical fibroids (about 10%), as well as intramural fibroids, subserosal fibroids and submucosal fibroids. Most patients with uterine fibroids have no obvious symptoms and are only discovered accidentally during physical examinations. Some patients may experience menstrual disorders (such as increased menstrual flow, prolonged menstrual period, etc.), abdominal masses, frequent urination, increased leucorrhea, lower abdominal distension and other symptoms. When fibroids compress the bladder and rectum, it can cause dysuria, painful defecation and constipation.

[0003] Uterine fibroids are more common in women aged 30 to 50, and are less common in women under 20. Women of childbearing age are at high risk, with a prevalence of about 25%. At the same time, the incidence rate in perimenopausal women cannot be ignored, accounting for about 10%. Those with polycystic ovary syndrome, a family history of uterine fibroids, and long-term use of hormone drugs have a higher risk of developing the disease.

[0004] The etiology and pathogenesis of uterine fibroids are still unclear, and may be related to genetic susceptibility, sex hormone levels, and stem cell dysfunction. The daughters of patients with uterine fibroids have an increased risk of the disease, and the probability of monozygotic twins having uterine fibroids at the same time is much higher than that of dizygotic twins. 40% to 50% of patients with uterine fibroids have abnormal chromosome structure, indicating that genetic factors play an important role in the development of uterine fibroids. Although the role and mechanism of estrogen and progesterone in the development of uterine fibroids have not yet been fully clarified, a large number of clinical observations and experimental results have shown that uterine fibroids are a hormone-dependent tumor.

[0005] As the exact cause is unknown, modern Western medicine uses sex hormones or surgical resection for treatment, and there is no other ideal treatment. Surgical treatment causes local damage to the entire organ of the human body, and increases the patient's pain and economic burden. Sequelae are inevitable after the operation.

[0006] Currently, there are very few Chinese patent medicines for the treatment of uterine fibroids on the market, which cannot meet social needs. On the other hand, the efficacy of these old medicines is still not particularly ideal, and there is a need to develop Chinese patent medicines with further improved efficacy. Summary of the invention

[0007] In order to solve the above problems, the present invention provides an application of a Chinese medicine composition in the preparation of a drug for treating uterine fibroids. The Chinese medicine composition is effective in treating uterine fibroids without toxic side effects, and provides important clinical value to make up for the small number of such Chinese patent medicines and poor efficacy on the market.

[0008] The present invention provides the following technical solutions: A use of a Chinese medicine composition in preparing a drug for treating uterine fibroids, wherein the Chinese medicine composition is made from the following raw materials in parts by weight: 1-25 parts of peach kernel (fried), 2-40 parts of myrrh (fried), 2-40 parts of salvia miltiorrhiza, 2-20 parts of red peony root, 2-20 parts of safflower, 2-30 parts of zedoaria, 2-20 parts of fenugreek (fried), 2-30 parts of gleditsia thorn, 2-60 parts of patrinia herb, 2-60 parts of dandelion, 1-25 parts of toosendan fruit, 2-40 parts of angelica dahurica, 2-40 parts of pyrrosia, and 1-20 parts of wolfberry.

[0009] Furthermore, the preparation method of the Chinese medicine composition is as follows: Take the above weight portions of myrrh (fried), Gleditsia sinensis, and Angelica dahurica, and grind them into fine powder; add water to the remaining 11 raw materials and boil them for 2 to 4 times, each time for 0.5 to 2 hours, combine the extracts, filter, concentrate the filtrate into a thick paste, add the above fine powder, dry, continue to grind into fine powder, mix well, and finally process it into an oral preparation to obtain.

[0010] Furthermore, the oral preparation is a powder, capsule, tablet, granule or pill.

[0011] Furthermore, the Chinese medicine composition is made from the following raw materials in parts by weight: 15 parts of peach kernel (fried), 15 parts of myrrh (fried), 15 parts of salvia miltiorrhiza, 15 parts of red peony root, 15 parts of safflower, 15 parts of zedoaria, 15 parts of fenugreek (fried), 15 parts of gleditsia spinosa, 50 parts of patrinia herb, 50 parts of dandelion, 15 parts of toosendan fruit, 15 parts of the angelica dahurica, 25 parts of pyrrosia, and 15 parts of wolfberry fruit.

[0012] The beneficial effects of the present invention include but are not limited to: The Chinese medicine composition of the present invention comprises peach kernel, myrrh, salvia miltiorrhiza, red peony root, safflower, licorice, zedoaria and vaccaria as the main drugs, which play the effects of promoting blood circulation, removing blood stasis, reducing swelling and relieving pain; dandelion, patrinia and pyrrosia are used as the assistant drugs, which are mainly used to clear dampness and heat; wolfberry fruit is used to nourish the kidney and benefit the essence; angelica dahurica and Toosendan fruit are used to regulate qi and dredge the meridians, and guide all the drugs to the diseased area, which are the guiding drugs. The Chinese medicine composition is compatible with the whole prescription, has the effects of promoting blood circulation, removing blood stasis, detoxifying and reducing swelling, regulating qi and relieving pain, and nourishing the kidney and benefiting the essence, and is used for diseases such as female uterine fibroids caused by qi stagnation and blood stasis, and internal accumulation of blood stasis and heat.

[0013] The results of animal experiments show that the Chinese medicine composition of the present invention has a drug effect equivalent to that of the existing therapeutic drug mifepristone; after administration, the uterine coefficient and the levels of estradiol and progesterone in the model animals are significantly reduced; and the Bax content in uterine fibroid cells is significantly reduced and the expression of Bax is increased, which is beneficial to promote the apoptosis of uterine fibroid cells, thereby treating uterine fibroids. DETAILED DESCRIPTION

[0014] In order to clearly illustrate the technical features of this solution, the present invention is described in detail below through specific implementation methods. The scope of the present invention is not limited to the following embodiments. Professionals in the field can understand that various changes and modifications can be made to the present invention without departing from the spirit and scope of the present invention.

[0015] Example 1 This embodiment is a hard capsule preparation of the Chinese medicine composition of the present invention.

[0016] The prescription is: Myrrh (fried) 500g, Gleditsia thorn 500g, Angelica dahurica powder 500g, Peach kernel (fried) 500g, Salvia miltiorrhiza 500g, Red Peony Root 500g, Carthamus 500g, Eupatorium fortunei 500g, Vaccaria segetalis (fried) 500g, Patrinia 1666g, Taraxacum mongolicum 1666g, Toosendan fruit 500g, Pyrola 833g, Lycium barbarum 500g.

[0017] The preparation method is as follows: take 500g of myrrh (fried), 500g of Gleditsia sinensis thorn, and 500g of Angelica dahurica powder, crush them into fine powder and set aside; take another 500g of peach kernel (fried), 500g of Salvia miltiorrhiza, 500g of red peony root, 500g of safflower, 500g of Zedoaria, 500g of Vaccaria segetalis (fried), 1666g of Patrinia scabra, 1666g of Taraxacum mongolicum, 500g of Toosendan fruit, 833g of Pyrrosia dahurica, and 500g of Lycium barbarum, mix them, add 65L of water and boil them twice, each time for 1 hour, combine the extracts, filter, and concentrate the filtrate into a thick paste, add the above-mentioned reserved fine powder, dry, crush into fine powder, sieve to make fine powder, mix well, and put into Ming capsules to make hard capsules.

[0018] Dosage: Oral. 4-6 capsules at a time, 3 times a day; or as directed by your doctor.

[0019] Example 2 This embodiment is a water pill of the Chinese medicine composition of the present invention.

[0020] Prescription: Myrrh (fried) 400g, Gleditsia thorn 400g, Angelica dahurica powder 400g, Peach kernel (fried) 500g, Salvia miltiorrhiza 500g, Red Peony Root 500g, Carthamus 500g, Eupatorium fortunei 500g, Vaccaria segetalis (fried) 500g, Patrinia 1666g, Taraxacum mongolicum 1666g, Toosendan fruit 500g, Pyrrosia 833g, Lycium barbarum 500g.

[0021] The preparation method is as follows: take 400g of myrrh (fried), 400g of Gleditsia sinensis thorn, and 400g of Angelica dahurica powder, crush them into fine powder and set aside; take 500g of peach kernel (fried), 500g of Salvia miltiorrhiza, 500g of red peony root, 500g of safflower, 500g of Zedoaria, 500g of Vaccaria segetalis (fried), 1666g of Patrinia scabra, 1666g of Taraxacum mongolicum, 500g of Toosendan fruit, 833g of Pyrrosia dahurica, and 500g of Lycium barbarum, mix them, add 65L of water and boil them twice, each time for 1 hour, combine the extracts, filter, concentrate the filtrate into a thick paste, add the above-mentioned reserved fine powder, dry, crush into fine powder, sieve to make fine powder, mix well, and make water pills with water.

[0022] Dosage: Oral. 20-30 capsules at a time, 3 times a day; or as directed by your doctor.

[0023] Example 3 This embodiment is a tablet of the Chinese medicine composition of the present invention.

[0024] Prescription: Myrrh (fried) 500g, Gleditsia thorn 500g, Angelica dahurica powder 500g, Peach kernel (fried) 400g, Salvia miltiorrhiza 400g, Red Peony Root 400g, Carthamus 400g, Eupatorium fortunei 400g, Vaccaria segetalis (fried) 400g, Patrinia 1500g, Taraxacum mongolicum 1500g, Toosendan fruit 400g, Pyrrosia 800g, Lycium barbarum 400g.

[0025] The preparation method is as follows: take 500g of myrrh (fried), 500g of Gleditsia sinensis thorn, and 500g of Angelica dahurica powder, crush them into fine powder and set aside; take 400g of peach kernel (fried), 400g of Salvia miltiorrhiza, 400g of red peony root, 400g of safflower, 400g of Zedoaria, 400g of Vaccaria segetalis (fried), 1500g of Patrinia scabra, 1500g of Taraxacum mongolicum, 400g of Toosendan fruit, 800g of Pyrrosia sinensis, and 400g of Lycium barbarum, mix them, add 65L of water and boil them twice, each time for 1 hour, combine the extracts, filter, concentrate the filtrate into a thick paste, add the above-mentioned fine powder and soluble starch to make tablets.

[0026] Dosage: Oral. 4-6 tablets at a time, 3 times a day; or as directed by your doctor.

[0027] The fine powders of the pharmaceutical preparations in Examples 1-3 above were respectively taken to prepare suspensions for animal experiments.

[0028] The following is an animal experiment on a uterine fibroid model to experimentally study and verify the effects of the Chinese medicine composition of the present invention and the samples prepared in the comparative example on treating uterine fibroids.

[0029] 1. Experimental Animals SD rats, female, 180-220 g, from Liaoning Changsheng Biotechnology Co., Ltd. (Animal Certificate No. SCXK(Liao)2015-0001). They were randomly divided into 8 groups, 10 rats in each group; blank control group, model control group, positive control group, and test drug group (5 groups).

[0030] 2. Drugs under investigation 2.1 Chinese medicine composition example 1: Corresponding Example 1 Pharmacy Prescription and Preparation, take Myrrh (fried) 500g, Gleditsia thorn 500g, Angelica dahurica powder 500g, crush into fine powder, standby; separately take peach kernel (fried) 500g, Salvia miltiorrhiza 500g, red peony root 500g, safflower 500g, Ze Lan 500g, Vaccaria segetalis (fried) 500g, Patrinia 1666g, Taraxacum 1666g, Toosendan 500g, Pyrrosia 833g, Lycium barbarum 500g, mix, add 65L water to decoct, decoct 2 times, each time for 1 hour, extracts are combined, filtered, filtrate is concentrated into a thick paste, the above-mentioned standby fine powder is added, dried, crushed into fine powder, and mixed. Take an appropriate amount of fine powder and add it to distilled water to make a suspension with a concentration of 1.0g crude drug / mL.

[0031] 2.2 Chinese medicine composition example 2: Corresponding Example 2 Pharmacy Prescription and Preparation, take Myrrh (fried) 400g, Gleditsia thorn 400g, Angelica dahurica powder 400g, crush into fine powder, standby; take another peach kernel (fried) 500g, Salvia miltiorrhiza 500g, Red Peony 500g, Carthamus 500g, Ze Lan 500g, Vaccaria segetalis (fried) 500g, Patrinia 1666g, Taraxacum 1666g, Toosendan Fructus 500g, Pyrrosia 833g, Lycium barbarum 500g, mix, add 60L water decoction, decoct 2 times, each time for 1 hour, extracts are combined, filtered, filtrate is concentrated into a thick paste, the above-mentioned standby fine powder is added, dried, crushed into fine powder, and mixed. Take an appropriate amount of fine powder and add it to distilled water to make a suspension with a concentration of 1.0g crude drug / mL.

[0032] 2.3 Chinese medicine composition example 3: Corresponding Example 3 Pharmacy Prescription and Preparation, take Myrrh (fried) 500g, Gleditsia thorn 500g, Angelica dahurica powder 500g, crush into fine powder, standby; take another peach kernel (fried) 400g, Salvia miltiorrhiza 400g, Red Peony 400g, Carthamus 400g, Ze Lan 400g, Vaccaria segetalis (fried) 400g, Patrinia 1500g, Taraxacum 1500g, Toosendan 400g, Pyrrosia 800g, Lycium barbarum 400g, mix, add 55L water and boil, boil twice, the first time for 1 hour, the second time for 0.5 hours, the extracts are combined, filtered, the filtrate is concentrated into a thick paste, the above-mentioned standby fine powder is added, dried, crushed into fine powder, and mixed. Take an appropriate amount of fine powder and add it to distilled water to make a suspension with a concentration of 1.0g crude drug / mL.

[0033] 2.4 Comparative Example A Take 400g of Gleditsia sinensis thorn and 300g of Angelica dahurica powder, crush them into fine powder and set aside; take 400g of peach kernel (fried), 200g of Salvia miltiorrhiza, 400g of red peony root, 200g of safflower, 200g of Patrinia scabra, 300g of dandelion, 400g of Toosendan fruit, 200g of Pyrola, and 500g of Lycium barbarum, mix them, add 25L of water and boil them twice, each time for 1 hour, combine the extracts, filter, and concentrate the filtrate into a thick paste, add the above-mentioned fine powder, dry, grind into fine powder, mix well, take an appropriate amount of fine powder and add it to distilled water to make a suspension with a concentration of 1.0g crude drug / mL.

[0034] 2.5 Comparative Example B Take 200g of myrrh (fried) and 200g of Gleditsia sinensis, crush them into fine powder and set aside; take 400g of red peony root, 400g of zedoaria, 300g of fenugreek (fried), 300g of patrinia herb, 300g of dandelion, 300g of toosendan fruit, 100g of pyrrosia, and 400g of wolfberry, mix them, add 20L of water and boil them twice, the first time for 1 hour and the second time for 0.5 hour, combine the extracts, filter, and concentrate the filtrate into a thick paste, add the above-mentioned fine powder, dry, crush into fine powder, mix well, take an appropriate amount of fine powder and add it to distilled water to make a suspension with a concentration of 1.0g crude drug / mL.

[0035] 2.6 Positive control drug Mifepristone (Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., production batch number: 05210301, specification: 25 mg / tablet).

[0036] 3. Modeling The blank group received an intramuscular injection of 1 mL / 100 g normal saline once a day for 6 consecutive weeks.

[0037] The remaining groups were injected intramuscularly with estradiol benzoate (0.5 mg / kg) once a day, and progesterone (4 mg / kg) was added once a week for 5 consecutive weeks. In the 6th week, two hormones were injected simultaneously, with the same dosage as above, once a day. After the modeling was completed, one rat was randomly selected from each group to test the content of estradiol (E2) and progesterone (P), and the uterine coefficient was measured to determine whether the model was successful.

[0038] IV. Experimental Procedure The blank group and the model control group were gavaged with the same volume of normal saline daily; the positive control group was intraperitoneally injected with 1.25 mg / kg of mifepristone (McLean Co., Ltd.) once a day; the aforementioned Chinese medicine composition examples 1, 2, 3 of the present invention and the suspension of comparative examples A and B were gavaged with 1 mL / 100 g each time, once in the morning and evening every day, and each group was continuously administered for 4 weeks.

[0039] 5. Indicator Observation 5.1 Content of estradiol (E2) and progesterone (P) Four weeks later, the rats were intraperitoneally anesthetized with sodium pentobarbital (40 mg / kg), blood was collected from the aorta, and the serum was centrifuged. The levels of estradiol (E2) and progesterone (P) were determined according to the kit method.

[0040] 5.2 Uterine coefficient The uterus of the rats was separated, and the morphology and color of the uterus of each group of rats were observed with the naked eye, weighed, and the uterus coefficient was calculated. Uterine coefficient (%) = (m 子宫 / m 体重 )×100%; among them, estradiol detection kit and progesterone detection kit were purchased from Shanghai ELISA Biotechnology Co., Ltd.

[0041] 5.3 Immunohistological observation Immunohistochemistry was used to detect the expression of Bcl-2 and Bax in uterine fibroids. Bcl-2 is a proto-oncogene that can prevent apoptosis and prolong cell lifespan. Bax gene can counteract the activity of Bcl-2 and directly promote apoptosis.

[0042] Grading standard: Semi-quantitative judgment was made based on the proportion of positive cells and staining intensity.

[0043] The staining intensity was evaluated according to the following criteria: Negative was scored as 0 points; weak staining but significantly stronger than the negative control was scored as 1 point; moderate staining intensity was scored as 2 points; and strong staining was scored as 3 points.

[0044] The percentage of positive cells stained was evaluated based on the following criteria: The number of positive cells <5% was negative: 0 points; 6%-15% was weakly positive: 1 point; 16%-30% was positive: 2 points; >31% was strongly positive: 3 points.

[0045] Comprehensive score: The two scores are added together and the results are divided into 4 levels: 0 to 1 points are (-); 2 points is (+); 3 to 4 points is (++); 5 to 6 points is (+++).

[0046] The changes in slice indicators were evaluated according to the comprehensive score level.

[0047] 6. Statistical Methods SPSS 13.0 statistical software was used for statistical analysis of the data. The measurement data were expressed as ±s and tested with t test. The counting data were tested with rank sum test. P < 0.05 was considered statistically significant.

[0048] VII. Experimental Results 7.1 Effects of the test samples on rat uterine coefficient and hormone levels As can be seen from the data in Table 1 below, the uterine coefficient, serum estradiol and progesterone levels of the model group rats were significantly higher than those of the blank control group (P < 0.01), indicating that the modeling was successful.

[0049] After administration according to the aforementioned "four", the uterine coefficient and the levels of estradiol and progesterone in the positive control group and the Chinese medicine composition examples 1-3 were significantly reduced, indicating that mifepristone and the composition of the present invention can reduce the rat uterine coefficient and the levels of estrogen and progesterone in serum, that is, the effect of the Chinese medicine composition examples 1-3 of the present invention on the treatment of rat uterine fibroids is equivalent to mifepristone. In comparative examples A and B, the rat uterine coefficient and the levels of estrogen and progesterone in serum were not significantly different from those in the model group, indicating that their therapeutic effects were significantly worse than those of the Chinese medicine composition examples 1-3 of the present invention.

[0050]

[0051] 7.2 Effects of the test samples on the contents of Bcl-2 and Bax in uterine muscle cells As can be seen from the data in Table 2, the Bcl-2 protein-positive cells in the cytoplasm of uterine smooth muscle cells of the blank control group were mostly weakly positive and scattered; the number of Bcl-2 protein-positive cells in the cytoplasm of uterine smooth muscle cells of the model group rats increased significantly, and compared with the blank control group, there was a significant difference in the positive expression of Bcl-2 between the two (P<0.05). Compared with the model group, the number of Bcl-2 protein-positive cells in the cytoplasm of uterine smooth muscle cells of the positive control group and the Chinese medicine composition examples 1, 2, and 3 of the present invention rats was significantly reduced, and the intensity was significantly weakened, which was significantly different from the model group (P<0.05). The results show that the Chinese medicine composition of the present invention can significantly reduce the content of Bcl-2 protein in the muscle cells of uterine fibroid model rats, and the effect is equivalent to that of the control drug mifepristone; there is no significant difference between the comparative examples A and B and the model group.

[0052]

[0053] As shown in Table 3, the expression level of Bax in the model group rats was lower than that in the blank control group, and the difference was statistically significant (P<0.05). The expression levels of Bax in the positive control group and the rats in groups 1, 2, and 3 of the Chinese medicine composition of the present invention were higher than those in the model group, and the difference was statistically significant (P<0.05), indicating that the Chinese medicine composition of the present invention can increase the expression of Bax in the rat model of uterine fibroids. There was no significant difference between the comparative groups A and B and the model group.

[0054]

[0055] 8. Preliminary Toxicity Studies The acute toxicity test showed that the sample of Example 1 was administered to mice at 13 g / kg / time, i.e., the dosage was more than 100 times the daily dosage of a human (70 kg). The drug was administered orally 3 times within 24 hours and observed for one week. No abnormality was found and no animal died. According to the tolerance test requirements, when mice can tolerate 60-100 times the adult dose, the tolerance test screening can be considered qualified. The dosage of the sample of Example 1 far exceeds the above requirements, so the Chinese medicine composition can be considered to be relatively safe.

[0056] The long-term toxicity test showed that the sample of Example 1 was administered to the three groups of mice, A, B, and C, at 0.65g / 100g, 0.39g / 100g, and 0.13g / 100g, respectively, which were equivalent to 50 times, 30 times, and 10 times the human dosage, respectively. During the 180 days of continuous administration, no abnormality was found in the appearance and activities of the animals. The weight of the animals in each group continued to increase. At the end of the experiment, the weight of the large (A group), medium (B group), small (C group) dose and the control group increased by 249.5g, 240.0g, 232.0g, and 226.5g, respectively, compared with that before administration. The difference before and after administration was extremely significant (P<0.001), but there was no difference between the groups (P>0.05), indicating that the test sample did not affect the animal's food intake and weight gain under the experimental conditions. At the end of the experiment, no abnormalities were found during the macroscopic observation of the dissection, and no pathological changes related to the test samples were found during pathological microscopic examination of important organs (heart, liver, lungs, kidneys, testicles, ovaries, etc.), indicating that the Chinese medicine composition is relatively safe.

[0057] The above is only the embodiment of the present application, and the protection scope of the present application is not limited by these specific embodiments, but is determined by the claims of the present application. For those skilled in the art, the present application can have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the technical ideas and principles of the present application should be included in the protection scope of the present application.

Claims

1. Use of a Chinese medicine composition in preparing a drug for treating uterine fibroids, characterized in that: The Chinese medicine composition is made from the following raw materials in parts by weight: 1-25 parts of stir-fried peach kernels, 2-40 parts of stir-fried myrrh, 2-40 parts of salvia miltiorrhiza, 2-20 parts of red peony root, 2-20 parts of safflower, 2-30 parts of zedoaria, 2-20 parts of stir-fried vaccaria, 2-30 parts of gleditsia spinosa, 2-60 parts of patrinia herb, 2-60 parts of dandelion, 1-25 parts of toosendan fruit, 2-40 parts of angelica dahurica, 2-40 parts of pyrrosia, and 1-20 parts of wolfberry fruit.

2. The use according to claim 1, characterized in that: The preparation method of the Chinese medicine composition is as follows: Take the above-mentioned fried myrrh, Gleditsia sinensis and Angelica dahurica in proportion by weight and grind them into fine powder; add water to the remaining 11 raw materials and boil them for 2 to 4 times, each time for 0.5 to 2 hours; combine the extracts, filter and concentrate the filtrate into a thick paste; add the above-mentioned fine powder, dry and continue to grind into fine powder, mix well and finally process into an oral preparation.

3. The use according to claim 2, characterized in that: The oral preparation is powder, capsule, tablet, granule or pill.

4. The use according to claim 1 or 2, characterized in that: The Chinese medicine composition is made from the following raw materials in parts by weight: 15 parts of stir-fried peach kernels, 15 parts of stir-fried myrrh, 15 parts of salvia miltiorrhiza, 15 parts of red peony root, 15 parts of safflower, 15 parts of herba zedoariae, 15 parts of stir-fried vaccariae, 15 parts of gleditsia spinosa, 50 parts of herba patriniae, 50 parts of herba dandelions, 15 parts of fructus toosendan, 15 parts of the angelica dahurica, 25 parts of pyrrosiae, and 15 parts of fructus wolfberries.

Images